Related Experiment Video
Updated: Jan 10, 2026

Biotribological Testing and Analysis of Articular Cartilage Sliding against Metal for Implants
Published on: May 14, 2020
Minimum ten years follow-up of total knee arthroplasty using morphometric implants in patients with osteoarthritis
Ernest Siret1, Fabio Sammartino1, Florent Bernard De Villeneuve1
1Marseille Public University Hospital System, Marseille, France.
Purpose:
The aim of this study was to report the 10-year clinical and radiological outcomes, survivorship, and patient-reported results of the Persona posterior-stabilized (PS) total knee arthroplasty (TKA) performed in a single centre.
Methods:
This retrospective cohort study was based on a prospectively institutional database. A total of 293 primary Persona PS TKAs performed between 2012 and 2015 were identified. After applying inclusion and exclusion criteria, 185 knees (168 patients) were available for analysis at a minimum follow-up of ten years. Clinical evaluation included the Knee injury and Osteoarthritis Outcome Score (KOOS) and the 2011 Knee Society Score (KSS). Radiological assessment consisted of the hip-knee-ankle (HKA) angle. Implant survivorship was analyzed using Kaplan-Meier methods.
Results:
At 10 years, Kaplan-Meier survivorship for revision for any reason was 94.1% (95% CI 90.3-97.9%). Four revisions were performed (2 infections, 2 aseptic loosening). Mean KOOS scores improved significantly from preoperative to ten year follow-up (Pain 48→86; Symptoms 45→84; ADL 50→89; Sport 25→72; QoL 30→82; all p < 0.001). The KSS 2011 domains also significantly improved. The mean postoperative HKA angle was 179° ± 2°, with 7.8% of knees outside ± 3° from neutral. No radiographic evidence of radiolucent lines, osteolysis, or loosening was observed.
Conclusion:
At ten years, the Persona PS knee system demonstrated excellent survivorship and durable functional results comparable to other contemporary TKA designs. Further comparative studies are required to determine whether its morphometric concept provides additional clinical benefit.
Level Of Evidence:
IV Retrospective cohort study.

